Wastewater Analysis Suggests Rising Ketamine Use in Switzerland

Switzerland is grappling with a stark new reality: Ketamine consumption is soaring. New data released for the first half of 2025 reveals an undeniable upward trajectory in the use of the dissociative anesthetic, shattering the illusion that the drug is a fringe substance. The Swiss Federal Institute of Aquatic Science and Technology (Eawag) has uncovered this trend through rigorous wastewater analysis, a method that strips away self-reporting bias and exposes the raw truth of public consumption.

While Ketamine remains a critical medical tool for anesthesia, the sheer volume detected in Swiss sewage systems points to something far more pervasive than hospital use. The figures published by the substance-monitoring portal Dromedario are not just a statistical blip; they represent a marked increase that demands immediate attention. As "Special K" moves from the fringes of the underground to the mainstream, Swiss health officials are now confronting a rapidly evolving drug landscape that is outpacing traditional monitoring methods.

Zurich has emerged as the undisputed capital of this new wave of consumption. The data is unequivocal: concentrations of Ketamine in Zurich's wastewater significantly exceed the average of the ten other Swiss sites tested. This is not a nationwide plateau; it is a localized explosion centered on Switzerland's financial and cultural hub.

The timing of these spikes is even more telling. Levels surge dramatically during the weekends, providing a smoking gun for recreational abuse. While the chemical analysis cannot distinguish between a surgical patient and a club-goer, the distinct "weekend gap" confirms that the party scene is driving this increase. In the clubs and nightlife districts of Zurich, where the drug is colloquially known as "K" or "Ket," the wastewater tells a story of intense, episodic binging that fades by Monday morning, only to reignite the following Friday.

The rise in consumption brings with it a devastating physical toll that many users underestimate. This is not a harmless high; frequent use is directly linked to severe cognitive impairment, dependence, and catastrophic physical damage. The most alarming consequence is "ketamine bladder," a condition so severe it can lead to irreversible organ failure.

Medical professionals are sounding the alarm as they witness the downstream effects of this statistical surge. In extreme cases, the damage to the bladder lining is so extensive that reconstruction is impossible, necessitating surgical removal of the organ. As the popularity of "Ket" grows in social settings, a wave of long-term health complications is building in the background. The wastewater data is a warning sign: if consumption continues to climb at this rate, the Swiss healthcare system must brace for a corresponding spike in complex, life-altering surgeries.

While Ketamine grabs the headlines, the wastewater analysis reveals a complex shifting of the entire Swiss drug market. Crack cocaine is staging a worrying comeback. Researchers tracking AEME—the chemical marker produced when crack is smoked—have recorded noticeable increases in 2025. Like Ketamine, this trend is most pronounced in Zurich and Chur, with similar weekend peaks indicating a volatile recreational market.

In a surprising contrast, traditional staples of the drug trade appear to be losing their grip. Methamphetamine usage has declined slightly nationwide since 2021. Even Cannabis, long a staple of recreational use, is seeing a downturn. Concentrations of THC-COOH, the metabolic byproduct of marijuana, were lower in the first two quarters of 2025 compared to previous years. This divergence suggests a significant behavioral shift among Swiss users, moving away from sedatives and stimulants like weed and meth toward the dissociative effects of Ketamine and the intense highs of crack cocaine.

Wastewater analysis has cemented itself as the most honest barometer of societal habits. Surveys can be lied to; sewage cannot. While the technology cannot identify individual users, it provides an unvarnished, aggregate snapshot of what the population is actually consuming. The premise is simple but powerful: what flows through the treatment plants is the biological receipt of the nation's consumption.

For Ketamine, the direction of travel is unmistakably upward. This data provides policymakers and health organizations with the critical intelligence needed to adapt harm reduction strategies in real-time. We are no longer guessing about drug trends; we are measuring them down to the microgram. As Switzerland confronts these rising numbers, the clarity provided by Eawag's research is the first step in addressing a growing public health challenge that shows no sign of slowing down.